Clarkston Consulting
Skip to content

Clarkston Life Science SME Shares Guest Column on an Acquisition in the Biopharma Industry

February 12, 2024 |  Clarkston Consulting’s Janel Firestein was recently featured as guest columnist with Outsourced Pharma for perspectives on the recent Catalent acquisition in the biopharma industry. Read a few excerpts from the piece below or the full article here.

What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?

There are several areas where companies need to have strong vendor management practices. An organization’s vendor management discipline and risk management strategies are critical to ensure operations’ continuity, which has a direct impact on the ability to keep clinical trials running and serve the patients involved.

Mismanaged vendors have real impacts to your organization. These could include increased material costs, increased time on manufacturing and testing, and the ultimate risk that you may be unable to produce your own product. As such, it is important for companies to assess the maturity of their vendor management capabilities, define a tier-based vendor management approach, and implement improvements in a practical and phase-based manner that will mitigate these impacts.

Read the Full Article Here